Tagged with Global

Spain Spanish mid-cap Esteve is selling a 26 percent stake in the company to German private investment firm Lubea, a move it says will supply the necessary funds to further pursue its redefined company strategy while stepping up growth and allowing for additional international expansion. Expansion: Products and Geographies Esteve, a…

Global Brendan Shaw examines the protracted efforts of global stakeholders to come together around a global pandemic treaty and outlines the benefits of constructive engagement on the part of the pharmaceutical industry to find new solutions, policy approaches and business models moving forward.    You never want a serious crisis to…

Global Global biopharma is increasingly moving towards biologic medicines, which promise a greater impact on patient’s lives than the small-molecule drugs that preceded them, but which come with significant added costs and complexity. Against this backdrop, biologic drug developers are leaning evermore on experienced contract development and manufacturing organizations (CDMOs), of…

USA Founded in 1980 “at the dawn of a biotechnology revolution,” Amgen has held its ground throughout its more than 40-year history with innovative approaches to drug discovery that have led to a number of breakthrough therapies. Chairman and CEO Bob Bradway recently spoke to the Money Maze podcast about the…

Global The top 20 pharmaceutical companies in the world for the past year, according to Pharmaceutical Executive’s latest annual rankings. Pfizer holds sway at the top of the leaderboard, with its BioNTech-partnered COVID-19 vaccine Comirnaty still generating an incredible USD 37.8 billion in 2022 and its COVID-19 antiviral Paxlovid adding a…

USA Astellas has steadily developed its immuno-oncology (IO) pipeline via both organic and inorganic means in recent years, with its early-phase IO projects now overseen by industry veteran Peter Sandor, the company’s SVP and IO Primary Focus Lead. Sandor explains the variety of exciting IO approaches in development at Astellas, how…

Global Several macro-trends affected the pharmaceutical industry in 2022, impacting its inventory position, writes Matthew Bardell, managing director of specialist inventory consultants nVentic. Bardell highlights findings in a recent report – including the fact that despite widely-reported medicine shortages, Big Pharma’s inventories grew significantly last year – and calls for a…

USA Speaking at the 2023 BIO International Convention Chris Viehbacher who joined Biogen as CEO only a few months ago, criticised the US’s Inflation Reduction Act (IRA), legislation that will allow Medicare to negotiate prices for the drugs it spends the most on as of 2026. Viehbacher, who was brought in…

USA While the COVID-19 pandemic was a global wake-up call for many, life sciences stakeholders argue that not enough is being done to address the rising threats of further health crises and equate health security with national security, a necessity that requires consistent public funding. In addition, as a recent panel…

USA During a panel discussion at the BIO International Convention, Peter Marks, director of the US FDA’s Center for Biologics Evaluation and Research (CBER) discussed the positive regulatory outcomes of the COVID-19 pandemic as well as the backlogs it created and the challenges of carrying the lessons learned forward.   At…

Australia After last year’s acquisition of Vifor Pharma, the firm’s largest ever, opened new avenues for diversification, the ground-breaking approval of the Hemgenix gene therapy for Hemophilia B was an equally significant moment for the company. New CEO Paul MacKenzie continues to pursue further growth for Australia’s largest biopharma company, investing…

Global The UHC2030 Private Sector Constituency (UHC2030 PSC), which is hosted by the World Bank Group, has released a statement on the private sector commitments toward universal health coverage (UHC), ahead of Multi-stakeholder Hearings on UHC that will take place in New York on 9th May 2023. The IFPMA’s Thomas Cueni…